Lifechanging cataracts treatment eliminates the need for surgery

A new treatment for cataracts could change how millions manage this common cause of blindness. Published in Investigative Ophthalmology and Visual Science, the study presents a non-surgical option that may someday replace the need for invasive procedures. The findings have sparked fresh hope for people whose vision fades as cataracts cloud their sight.

More than 65 million people live with cataracts, making it one of the world’s top causes of visual impairment. Until now, surgery has been the only reliable way to treat the condition. But this new approach could open the door to drug-based treatments, potentially reshaping care for patients everywhere.

Cataracts develop when proteins in the eye’s lens become disorganized. These proteins clump together, forming cloudy patches that scatter light before it reaches the retina. The result is blurred or blocked vision that worsens over time, often leaving people unable to drive, read, or recognize faces.

Though aging is the most common trigger, cataracts can also stem from too much sunlight, smoking, injury, or diseases like diabetes. Certain medications can increase risk as well. Regardless of the cause, the only proven fix has been surgery, where the clouded lens is swapped out for an artificial one.

Now, a team of global researchers led by Professor Barbara Pierscionek has turned that model on its head. Based at Anglia Ruskin University, where she serves as Deputy Dean for Research and Innovation, Pierscionek guided a study that looked beyond the scalpel. Her team sought a drug that could tackle cataracts at the molecular level.

They zeroed in on oxysterols—oxygen-rich forms of cholesterol involved in cellular processes. One specific compound showed promise as an anti-cataract agent. By targeting the protein structures inside the lens, the drug could help restore clarity without surgery. It's a bold step forward that may lead to easier, more accessible care for millions.

The researchers' objective was to restore the organization of proteins within the lens, thereby enhancing its ability to focus. Remarkably, their efforts were rewarded with a significant reduction in lens opacity, observed in 46% of the cases studied.

To validate the efficacy of the oxysterol compound, the research team conducted a series of advanced optical tests on a group of 35 mice. Among these, some mice were genetically altered to develop lens cloudiness, mimicking cataract formation through an alteration of their αB-crystallin or αA-crystallin proteins.

In a groundbreaking experiment, the researchers administered a single drop of the oxysterol compound VP1-001 directly onto the ocular surface of the right eye in 26 mice. Simultaneously, the left eyes received a neutral drop of cyclodextrin. Nine mice were left untreated to serve as a control group.

The focus of this treatment was the αA- and αB-crystallin mutations that are frequently associated with cataract development in aging individuals.

The outcomes of this pioneering study were nothing short of astonishing. The treatment with the oxysterol compound VP1-001 demonstrated a remarkable improvement in refractive index profiles, a crucial optical parameter essential for maintaining high focusing capacity, in 61% of the lenses tested. Additionally, the researchers observed a substantial 1.0-grade improvement in opacity in 46% of the treated mice.

Professor Barbara Pierscionek, the driving force behind this groundbreaking research and a member of the Medical Technology Research Centre at Anglia Ruskin University (ARU), expressed her excitement about the findings.

She stated, "This study has shown the positive effects of a compound that had been proposed as an anti-cataract drug but never before tested on the optics of the lens. It is the first research of this kind in the world."

Furthermore, Professor Pierscionek noted, "It has shown that there is a remarkable difference and improvement in optics between eyes with the same type of cataract that were treated with the compound compared to those that were not.

Improvements occurred in some types of cataract but not in all, indicating that this may be a treatment for specific cataracts. This suggests distinctions may need to be made between cataract types when developing anti-cataract medications. It is a significant step forward towards treating this extremely common condition with drugs rather than surgery."

The implications of this breakthrough are monumental. For the 65.2 million individuals globally living with cataracts, this research offers a glimmer of hope for a future where surgery may not be the only viable option. The ability to combat cataracts with pharmaceutical interventions could potentially transform the lives of countless individuals, particularly those for whom surgery is not a suitable or accessible option.

While further research and clinical trials are necessary to validate these promising results, the prospects are undeniably encouraging. The study's findings underscore the importance of personalized treatment approaches for specific types of cataracts, opening up avenues for targeted medications tailored to individual patient needs.

To determine whether you have a cataract, your doctor will review your medical history and symptoms, and perform an eye examination. Your doctor may conduct several tests, including:

Visual acuity test. A visual acuity test uses an eye chart to measure how well you can read a series of letters. Your eyes are tested one at a time, while the other eye is covered. Using a chart or a viewing device with progressively smaller letters, your eye doctor determines if you have 20/20 vision or if your vision shows signs of impairment.

Slit-lamp examination. A slit lamp allows your eye doctor to see the structures at the front of your eye under magnification. The microscope is called a slit lamp because it uses an intense line of light, a slit, to illuminate your cornea, iris, lens, and the space between your iris and cornea. The slit allows your doctor to view these structures in small sections, which makes it easier to detect any tiny abnormalities.

Retinal exam. To prepare for a retinal exam, your eye doctor puts drops in your eyes to open your pupils wide (dilate). This makes it easier to examine the back of your eyes (retina). Using a slit lamp or a special device called an ophthalmoscope, your eye doctor can examine your lens for signs of a cataract.

Applanation tonometry. This test measures fluid pressure in your eye. There are multiple different devices available to do this.

To deal with symptoms of cataracts until you decide to have surgery, try to:

Self-care measures may help for a while, but as the cataract progresses, your vision may deteriorate further. Consult a medical professional.

Note: Materials provided above by The Brighter Side of News. Content may be edited for style and length.

Like these kind of feel good stories? Get The Brighter Side of News' newsletter.